For 50 years, the KRAS mutation was untouchable.


It drives 90% of pancreatic cancers. Researchers spent decades trying to block it. Nothing worked. Oncologists stopped trying and called it "undruggable."
A new drug called daraxonrasib just proved them wrong.
Phase 3 trial. 500 patients. The hardest group... metastatic cases that had already failed chemotherapy.
It doubled their survival. Cut the risk of death by 60%.
Fifty years of "impossible" just became possible with one drug.
post-image
post-image
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments